布地奈德联合孟鲁司特钠治疗小儿支气管哮喘的疗效研究

Clinical efficacy of budesonide combined with montelukast sodium in the treatment of children bronchial asthma

目的观察布地奈德联合孟鲁司特钠治疗小儿支气管哮喘的临床疗效。方法选取东方市人民医院2013年11月—2015年12月收治的98例小儿支气管哮喘患儿,随机分为单一组与联合组,各49例。单一组应用布地奈德治疗,联合组应用布地奈德联合孟鲁司特钠治疗。观察两组患儿临床疗效、治疗前后肺功能指标〔用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、呼气峰值流速(PEF)及FEV1与FVC的比值(FEV1/FVC)〕及不良反应发生情况。结果联合组患儿总有效率高于单一组,差异有统计学意义(P<0.05)。治疗前,两组患儿肺功能指标比较,差异无统计学意义(P>0.05);治疗后,联合组患儿FEV1、FEV1/FVC、PEF、FVC高于单一组,差异有统计学意义(P<0.05)。两组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论布地奈德与孟鲁司特钠联合治疗小儿支气管哮喘可显著提高其临床疗效,可有效改善肺功能指标,且未增加不良反应。

Objective To observe the clinical curative of budesonide combined with montelukast sodium in the treatment of children bronchial asthma. Methods A total of 98 children with bronchial asthma were selected in the People's Hospital of Dongfang City from November 2013 to December 2015,which were randomly divided into single group and the combination group,49 cases in each. The single group was treated with budesonide,the combination group received budesonide combined with montelukast sodium. The clinical efficacy,pulmonary function indexes before and after treatment 〔forced vital capacity( FVC),forced expiratory volume in the first second( FEV1),peak expiratory flow( PEF) and ratio of FEV1 to FEV1/ FVC( FVC) 〕and occurrence of adverse reactions between the two groups were observed. Results The total effective rate of the combination group was higher than that of the single group( P < 0. 05). Before treatment,pulmonary function indicators between the two groups showed no significant differences( P > 0. 05); after treatment,FEV1,FEV1/ FVC,PEF,FVC of the combination group were higher than single group( P < 0. 05). There was no significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Budesonide combined with montelukast sodium in the treatment of children bronchial asthma can significantly improve the clinical efficacy,effectively improve lung function index,and do not increase the adverse reaction.